"studyTitle","studyAcronym","studyRationale","uuid:ID","studyVersion","id"
"Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","H2Q-MC-LZZT","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","441af45b-7a6e-4781-a857-2d031a01faa4","2","StudyVersion_1"
